Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium Tc-99m albumin diethylenetriaminepentaacetic acid
- Development stage
- Unknown
- Lead developer
- Nihon Medi-Physics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Technetium Tc-99m albumin diethylenetriaminepentaacetic acid (99mTc-HSA-D) is a radiopharmaceutical diagnostic agent developed by Nihon Medi-Physics. It consists of human serum albumin (HSA) labeled with the radioisotope technetium-99m using diethylenetriaminepentaacetic acid (DTPA) as a stable chelating agent. This specific chelation method provides high in-vivo stability and a prolonged blood retention rate compared to other HSA labeling techniques, making it an ideal tracer for blood pool imaging and the detection of protein leakage. Its primary clinical applications include protein leakage scintigraphy for diagnosing protein-losing gastroenteropathy, mammary lymphoscintigraphy for sentinel lymph node detection in breast cancer patients, and the evaluation of renal protein loss in nephrotic syndrome.
- Brand names
- 99mTc-HSA-D Injection
- Other names
- Technetium Tc-99m human serum albumin DTPATechnetium (99mTc) albumin (human) DTPA99mTc-labeled human serum albumin-DTPA
Beyond the preview
Go deeper on technetium Tc-99m albumin diethylenetriaminepentaacetic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium Tc-99m albumin diethylenetriaminepentaacetic acid.